Mangalam Drugs and Organics Ltd Stock Price Today (NSE: MANGALAM)
Fundamental Score
Mangalam Drugs and Organics Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Mangalam Drugs and Organics Ltd share price today is ₹32.21, up +0.00% on NSE/BSE as of 17 February 2026. Mangalam Drugs and Organics Ltd (MANGALAM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹41.78 (Cr). The 52-week high for MANGALAM share price is ₹N/A and the 52-week low is ₹N/A. The company has a Return on Equity (ROE) of 4.71% and a debt-to-equity ratio of 0.74.
Mangalam Drugs and Organics Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Mangalam Drugs and Organics Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Mangalam Drugs and Organics Share Price: A ROCE Efficiency Analysis
A key trend in the pharmaceutical industry is the increasing scrutiny of capital allocation efficiency. Companies are under pressure to demonstrate higher returns on invested capital, and this analysis focuses on how that impacts Mangalam Drugs and Organics share price. Currently trading at ₹35.74, the stock presents an interesting case study given its Return on Capital Employed (ROCE) of 8.03%. This analysis forms a small component of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, aimed at understanding the company's financial health. It is an observational review and not a recommendation to buy or sell.
The ROCE of 8.03% is a crucial metric for evaluating Mangalam Drugs and Organics Ltd. ROCE indicates how efficiently a company is utilizing its capital to generate profits. While a higher ROCE generally suggests better profitability, this level must be compared to the company's cost of capital and its peers to understand its true significance. An ROCE significantly above the cost of capital indicates value creation, while a lower ROCE can signal operational inefficiencies.
Comparing Mangalam Drugs and Organics Ltd to its peers offers further insights. For example,
Mankind Pharma Ltd often benefits from a perceived advantage in management quality, which can lead to more effective capital allocation and, consequently, potentially higher returns. Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd provide further benchmarks for comparison. Analyzing the ROCE of these peer companies against Mangalam Drugs and Organics Ltd will reveal whether the company is underperforming, outperforming, or performing in line with industry standards.The 8.03% ROCE impacts the company's potential economic moat. A strong economic moat protects a company's profits from competitors. Companies with higher ROCE have more resources to invest in research and development, marketing, or operational improvements, strengthening their competitive advantage. If Mangalam Drugs and Organics Ltd. can improve its ROCE, it could potentially build a stronger moat around its business. However, the current ROCE suggests that the moat is less robust compared to competitors with demonstrably higher capital efficiency. Further investigation is required to ascertain the drivers behind the ROCE and potential areas for improvement.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mangalam Drugs and Organics Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MANGALAM across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Cash Generation (₹27.93 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (50.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
11 factors identified
Below-Average Return on Equity (4.71%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.03%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-369.52%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-38.03%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (2.42% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-3.72% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-3.72% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-0.33x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (34.58%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Mangalam Drugs and Organics Ltd Financial Statements
Comprehensive financial data for Mangalam Drugs and Organics Ltd including income statement, balance sheet and cash flow
About MANGALAM (Mangalam Drugs and Organics Ltd)
Mangalam Drugs and Organics Ltd (MANGALAM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹41.78 (Cr). Mangalam Drugs and Organics Ltd has delivered a Return on Equity (ROE) of 4.71% and a ROCE of 8.03%. The debt-to-equity ratio stands at 0.74, reflecting the company's capital structure. Investors tracking MANGALAM share price can monitor key metrics including P/E ratio, promoter holding of 50.30%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
MANGALAM Share Price: Frequently Asked Questions
What is the current share price of Mangalam Drugs and Organics Ltd (MANGALAM)?
As of 17 Feb 2026, 10:14 am IST, Mangalam Drugs and Organics Ltd share price is ₹32.21. The MANGALAM stock has a market capitalisation of ₹41.78 (Cr) on NSE/BSE.
Is MANGALAM share price Overvalued or Undervalued?
MANGALAM share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Mangalam Drugs and Organics Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of MANGALAM share price?
The 52-week high of MANGALAM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Mangalam Drugs and Organics Ltd share price?
Key factors influencing MANGALAM share price include quarterly earnings growth (Sales Growth: -38.03%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Mangalam Drugs and Organics Ltd a good stock for long-term investment?
Mangalam Drugs and Organics Ltd shows a 5-year Profit Growth of -3.72% and an ROE of 4.71%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.74 before investing in MANGALAM shares.
How does Mangalam Drugs and Organics Ltd compare with its industry peers?
Mangalam Drugs and Organics Ltd competes with major peers in the Pharmaceuticals. Investors should compare MANGALAM share price P/E of 0.00x and ROE of 4.71% against the industry averages to determine competitive standing.
What is the P/E ratio of MANGALAM and what does it mean?
MANGALAM share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is MANGALAM performing according to Bull Run's analysis?
MANGALAM has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does MANGALAM belong to?
MANGALAM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Mangalam Drugs and Organics Ltd share price.
What is Return on Equity (ROE) and why is it important for MANGALAM?
MANGALAM has an ROE of 4.71%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Mangalam Drugs and Organics Ltd generates profits from shareholders capital.
How is MANGALAM debt-to-equity ratio and what does it indicate?
MANGALAM has a debt-to-equity ratio of 0.74, which indicates moderate leverage that should be monitored.
What is MANGALAM dividend yield and is it a good dividend stock?
MANGALAM offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Mangalam Drugs and Organics Ltd shares.
How has MANGALAM share price grown over the past 5 years?
MANGALAM has achieved 5-year growth rates of: Sales Growth 2.42%, Profit Growth -3.72%, and EPS Growth -3.72%.
What is the promoter holding in MANGALAM and why does it matter?
Promoters hold 50.30% of MANGALAM shares, with 34.58% pledged. High promoter holding often indicates strong management confidence in Mangalam Drugs and Organics Ltd.
What is MANGALAM market capitalisation category?
MANGALAM has a market capitalisation of ₹42 crores, placing it in the Small-cap category.
How volatile is MANGALAM stock?
MANGALAM has a beta of N/A. A beta > 1 suggests the Mangalam Drugs and Organics Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MANGALAM operating profit margin trend?
MANGALAM has a 5-year average Operating Profit Margin (OPM) of 9.61%, indicating the company's operational efficiency.
How is MANGALAM quarterly performance?
Recent quarterly performance shows Mangalam Drugs and Organics Ltd YoY Sales Growth of -38.03% and YoY Profit Growth of -369.52%.
What is the institutional holding pattern in MANGALAM?
MANGALAM has FII holding of 0.11% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Mangalam Drugs and Organics Ltd stock.